# ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) · Edgar & Edgarette company card

> Arcutis Biotherapeutics (ARQT) grew revenue 91.3% in FY2025 to $376 million, operating margin -3.3% against a -3.8% median for pharmaceutical preparations, equity 43.8% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1787306 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/ARQT) · [JSON](https://www.pops4.com/boards/company/ARQT.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $376M |
| Revenue growth, 1 year | 91.3% |
| Revenue growth per year | — |
| Operating margin | -3.3% (prior year -65.3%) |
| Net margin | -4.3% |
| Operating cash flow | −$6M |
| Capital spending | $686,000 |
| Free cash flow | −$6M |
| Cash | $43M |
| Long-term debt | $109M |
| Total assets | $433M |
| Total equity | $189M |
| Equity ÷ assets | 43.8% |
| Return on equity | -8.5% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -3.68 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Beneish M: -1.53 (above the −1.78 line)
- Health Harbor boat: Weathered boat · two warning signs · operating cash flow was negative; revenue is hard to predict: its 80% range is ±33%
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $376.1M (FY2025), total debt $109.0M. Experience: revenue up 91.3% on the year; operating margin -3.3%, up from -65.3%. Soundness: equity 43.8% of assets, return on equity -8.5%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $861.3M and $1.7B next year (method v4.1: its own 2-year record of growth weighed at 25% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $722.6M to $2.1B. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -3.3% against a -3.8% median; growth 91.3% against 13.7%.

Range logged 2026-10-29, receipt 713201821e272249, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 4, latest 2026-10-28 ([filing](https://www.sec.gov/Archives/edgar/data/1787306/000162828026067752/0001628280-26-067752-index.htm))

## Recent filings

- 8-K · filed 2026-10-28 · 5.02 Departure or Election of Directors; Appointment of Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1787306/000162828026067752/0001628280-26-067752-index.htm)
- 10-Q · filed 2026-08-05 · [filing](https://www.sec.gov/Archives/edgar/data/1787306/000178730626000051/0001787306-26-000051-index.htm)
- 8-K · filed 2026-08-05 · 2.02 Results of Operations and Financial Condition; 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1787306/000178730626000049/0001787306-26-000049-index.htm)
- 8-K · filed 2026-07-16 · 5.02 Departure or Election of Directors; Appointment of Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1787306/000162828026048469/0001628280-26-048469-index.htm)
- 8-K · filed 2026-06-09 · 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1787306/000162828026041883/0001628280-26-041883-index.htm)
- 10-Q · filed 2026-05-06 · [filing](https://www.sec.gov/Archives/edgar/data/1787306/000178730626000040/0001787306-26-000040-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001787306.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1787306

## Cite

POPS4, Edgar & Edgarette: ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) company card, from the company's own SEC filings, accessed 2026-10-29, https://www.pops4.com/boards/company/ARQT. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.